The potential of Fucoxanthin in bladder cancer treatment could be further underpinned by solid lines of in vivo evidence, including Fucoxanthin-induced suppression of xenografted bladder tumor growth, decreased levels of p-STAT3 and BCL-xL in Fucoxanthin-treated tumor tissues, and enhanced growth retardation of Cisplatin-treated bladder tumors when combined with Fucoxanthin. Here, BCL2L1 is linked to urinary bladder carcinoma.